COMP <GO>
GILD vs AMGN // FREE CASH FLOW YIELD
Gilead Sciences Inc. (NASDAQ) VS. Amgen Inc. (NASDAQ) • 15-METRIC TALLY: GILD 9
— AMGN 4
▲ FREE CASH FLOW YIELD LEADER: GILD
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
fcf-yield
4.60%
LAST: $466.01 (+1.15%) • MKT CAP: $249.09B
fcf-yield
3.25%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GILD VS. AMGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GILD | AMGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.80% | 67.20% | +11.60 | GILD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | 14.50% | +6.50 | GILD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 27.2x | -6.20 | GILD | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.60% | 3.25% | +1.35 | GILD | /fcf-yield <GO> |
| Operating Margin | 34.00% | 24.70% | +9.30 | GILD | /operating-margins <GO> |
| Net Profit Margin | 28.90% | 21.00% | +7.90 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) | 2.40% | 10.00% | -7.60 | AMGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.95% | 2.06% | -0.11 | AMGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 3.83 | +2.04 | GILD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.3 | 67.0 | -2.70 | AMGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.87 | +0.01 | GILD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.4x | 30.0x | -7.60 | GILD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $205.35B | $249.09B | -$43.74B | AMGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GILD REV | AMGN REV | GILD GROSS % | AMGN GROSS % | GILD FCF | AMGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | $36.75B | 78.8% | 67.2% | $9.46B | $8.10B |
| FY 2024 | $28.75B | $33.42B | 78.3% | 61.5% | $10.30B | $10.39B |
| FY 2023 | $27.12B | $28.19B | — | — | $6.79B | $7.20B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GILD // BETA 0.88
AMGN // BETA 0.87